A phase 1b/2, safety lead-in and dose-expansion trial of ivosidenib plus durvalumab and gemcitabine/cisplatin as first-line therapy in patients with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Memorial Sloan Kettering Cancer Center, University of Southern California, USC Norris Comprehensive Cancer Center, Kanagawa Cancer Center, CHA University Bundang Medical Center, CHA University, Seoul National University, Seoul National University Bundang Hospital, Yonsei Cancer Hospital, The Catholic University of Korea Seoul St. Mary's Hospital
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Servier
OpenAlex ID: W4410814299